We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Hartford Financial Services
HIG
$39.9B
| $32.2M | 0.08% |
670,795
+13,866
| +2% | +$671K |
|
277
Citizens Financial Group
CFG
$30.1B
| $32.2M | 0.08% |
931,224
+42,945
| +5% | +$1.57M |
|
278
Quest Diagnostics
DGX
$26B
| $32.2M | 0.08% |
327,549
-8,116
| -2% | -$774K |
|
279
Labcorp
LH
$25.2B
| $31.8M | 0.07% |
257,848
+14,509
| +6% | +$1.72M |
|
280
Ulta Beauty
ULTA
$21.8B
| $31.6M | 0.07% |
110,628
+1,233
| +1% | +$338K |
|
281
Fastenal
FAST
$54.8B
| $31.5M | 0.07% |
2,447,700
-8,724
| -0.4% | -$109K |
|
282
Northern Trust
NTRS
$21.8B
| $31.5M | 0.07% |
363,691
+8,209
| +2% | +$714K |
|
283
Monster Beverage
MNST
$95.1B
| $31.4M | 0.07% |
1,360,110
+20,210
| +2% | +$452K |
|
284
Vulcan Materials
VMC
$36.8B
| $31.3M | 0.07% |
259,592
+7,297
| +3% | +$892K |
|
285
Franklin Resources
BEN
$16.8B
| $31.2M | 0.07% |
741,162
-488
| -0.1% | -$20.2K |
|
286
Waters Corp
WAT
$37.3B
| $31M | 0.07% |
198,220
+6,849
| +4% | +$1.02M |
|
287
Molson Coors Class B
TAP
$8.02B
| $30.8M | 0.07% |
321,305
+8,348
| +3% | +$815K |
|
288
Freeport-McMoran
FCX
$86.2B
| $30.6M | 0.07% |
2,292,374
+125,720
| +6% | +$1.81M |
|
289
Essex Property Trust
ESS
$19.1B
| $30.6M | 0.07% |
132,243
+8,089
| +7% | +$1.86M |
|
290
Principal Financial Group
PFG
$24.3B
| $30.3M | 0.07% |
479,462
-16,842
| -3% | -$1.03M |
|
291
Royal Caribbean
RCL
$86.8B
| $29.9M | 0.07% |
305,227
+10,368
| +4% | +$970K |
|
292
Republic Services
RSG
$67.4B
| $29.8M | 0.07% |
474,473
+12,618
| +3% | +$755K |
|
293
Genuine Parts
GPC
$17.9B
| $29.6M | 0.07% |
320,295
+17,429
| +6% | +$1.68M |
|
294
Dentsply Sirona
XRAY
$2.84B
| $29.6M | 0.07% |
473,843
+64,648
| +16% | +$3.89M |
|
295
Idexx Laboratories
IDXX
$44.9B
| $29.4M | 0.07% |
190,010
-4,373
| -2% | -$603K |
|
296
Agilent Technologies
A
$39.6B
| $29.2M | 0.07% |
552,788
+4,697
| +0.9% | +$237K |
|
|
MJN
297
DELISTED
Mead Johnson Nutrition Company
MJN
| $29.2M | 0.07% |
327,878
+2,418
| +0.7% | +$199K |
|
298
J.M. Smucker
SJM
$13.5B
| $29.1M | 0.07% |
222,298
+12,396
| +6% | +$1.68M |
|
299
Microchip Technology
MCHP
$38.8B
| $29.1M | 0.07% |
789,432
+20,776
| +3% | +$732K |
|
|
LVLT
300
DELISTED
Level 3 Communications Inc
LVLT
| $29M | 0.07% |
507,651
+10,050
| +2% | +$580K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.